Comment on: ‘Subgroup effects in a randomized trial of different types and doses of exercise during breast cancer chemotherapy'

by Beijers, A J M, Verhulst, A L J, Mols, F, Vreugdenhil, G
Published 2015

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.

by Punt, C. J., van Herpen, C. M., Jansen, R. L., Vreugdenhil, G., Muller, E. W., de Mulder, P. H.
Published 1997

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: The introduction of a new measure

by Driessen, C. M. L., de Kleine-Bolt, K. M. E., Vingerhoets, A. J. J. M., Mols, F., Vreugdenhil, G.
Published 2011

Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice

by Razenberg, L. G. E. M., van Gestel, Y. R. B. M., de Hingh, I. H. J. T., Loosveld, O. J. L., Vreugdenhil, G., Beerepoot, L. V., Creemers, G. J., Lemmens, V. E. P. P.
Published 2016

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study

by Holtzer-Goor, K. M., Schaafsma, M. R., Joosten, P., Posthuma, E. F. M., Wittebol, S., Huijgens, P. C., Mattijssen, E. J. M., Vreugdenhil, G., Visser, H., Peters, W. G., Erjavec, Z., Wijermans, P. W., Daenen, S. M. G. J., van der Hem, K. G., van Oers, M. H. J., Uyl-de Groot, C. A.
Published 2015